BertinaAKoelemanRPCKosterT. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature1994; 369:64–7.
2.
DahlbackB. New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg 506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis. Thromb Haemost1995; 74:129–48.
3.
VandenbrouckeJPKosterTBrieE. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet1994; 344:1453–7.
4.
De StefanoVLeoneGMastrangeloS. Thrombosis during pregnancy and surgery in patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost1995; 74:793–4.
5.
FinazziGBrancaccioVMoiaM. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med1996; 100:530–6.
US Department of Health and Human Services. Agency for Health Care Policy and Research. Acute Pain Management: operative or medical procedures and trauma. Rockville (MD): The Agency; 1993. Clinical Practice Guideline No 1. AHCPR Publication No. 920023:107.
8.
ASCO. Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence based clinical practice guidelines. J Clin Oncol1996; 14(6):1957–60.
9.
ByrneJLHaynesAPRussellNH. Use of haemopoietic growth factors: commentary on the ASCO ECOG guidelines. Blood Reviews1997; 11:16–27.
10.
BinetJLAuquierADighieroG. A new prognostic classification of chronic lymphocytic leukaemia derived from a multivariate survival analysis. Cancer1981; 48:198–206.
11.
PasiJK. Gene therapy for haemophilia. Bailliere's Clinical Haematology1996; 9:305–17.
